Search

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a rare disease with poor prognosis if left untreated, characterized by pulmonary vascular bed obstruction due to unresolving thromboembolic material. The Hellenic pulmonary hypertension registry (HOPE) was launched in Greece in early 2015 and enrolls patients from all pulmonary hypertension subgroups in Greece. In total, 98 patients with CTEPH were enrolled from January 2015 until November 2019. Of these patients, 55.1% represented incident population, 50% were classified in the World Health Organization functional class II and 49% had a history of acute pulmonary embolism. The median values of pulmonary vascular resistance (PVR) and cardiac index were 7.4 (4.8) WU and 2.4 (1.0) L/min/m2, respectively, the mean diffusing capacity for carbon monoxide was 74.8 ± 20.6%, the median 6-minute walk distance was 347 (220) meters and the median value of N Terminal-pro brain natriuretic peptide was 506.0 (1450.0) pg/mL. In total, 60.2% of the patients were under pulmonary arterial hypertension-targeted therapy at the time of enrolment, specifically, riociguat was received by 35.7% of the patients and combination therapy was the preferred strategy for 16% of the patients. In total, 74 patients were evaluated for pulmonary endarterectomy (PEA), 34 (45.9%) were assessed as operable but only 23 of those (31.1%) finally underwent PEA. The remaining 40 patients were ineligible for PEA according to the operability assessment and 13 (17.6%) of them underwent balloon pulmonary angioplasty. The age of the non-operable patients was significantly higher than the operable patients (p &lt, 0.001), while there was no significant difference with regard to the history of coagulopathies between the operable and non-operable patients (p = 0.33).

Transcatheter aortic valve replacement (TAVR) is a rapidly proliferating technology with the potential to become the dominant treatment strategy for aortic valve stenosis in patients who are at excessive or high operative risk [(1)][1]. Antithrombotic therapy in the setting of TAVR has been

In patients with coarctation of aorta (CoA) aortic remodelling may alter the elastic properties of large arteries, but the role of stiffness indices, such as pulse wave velocity (PWV) and augmentation index (AIx), in CoA remains unclear. We studied the association between CoA, arterial stiffness and

Omega-3 polyunsaturated fatty acids (PUFAs) improve endothelial function and arterial stiffness in several patient groups and prevent heart failure (HF) progression. However the effects of omega-3 PUFAs on cardiac function and remodelling in patients with HF have not been adequately assessed. The